Since oxaliplatin/cisplatin-based chemotherapy is widely applied to CRC patients, their findings suggest that patients bearing higher plasma OPN are more resistant to those treatments and thus more susceptible to tumor progression and distant metastasis. This evidence concerns the gene SPP1 and neoplasm.